Ceva “State of the Art” Summit at VIV Asia 2015 >
Ceva’s poultry, swine, services & equipment teams will focus on what is “State of the Art” in animal production during the VIV Asia international trade show to be held in Bangkok from March 11th - 13th 2015.
Discover our newly redesigned website ceva.com ! >
To better meet your expectations, and improve user experience, our website has been completely revamped !
Happy new year 2015 ! >
Ceva Santé Animale wishes you all the best for 2015 !
Tildren® receives FDA approval to control clinical signs of Navicular Syndrome >
Tildren® is now available in the US
Ceva US Joins Fear Free™ Initiative As Inaugural Industry Sponsor >
Ceva today announced its commitment to Fear Free,™ an innovative initiative developed by “America’s Veterinarian” Dr. Marty Becker to in his words, “take the pet out of petrified and get pets back into practices.” The multi-year agreement aligns with Ceva’s leadership role and expertise in the area of pet behavior.
Egypt study confirms that a single rHVT-H5 hatchery vaccination could be an effective tool to address A/H5N1 prevention >
Research confirms that in endemic countries the classical inactivated vaccines are less effective and hard to administer, while application of a rHVT vector hatchery vaccine is labour saving, cost effective and provides clinical protection against various types of H5N1 Highly Pathogenic Avian Influenza Virus after a single dose.
Ceva Santé Animale reinforces its pharmaceutical production capacity, opening a new plant at its headquarters in Libourne France >
Libourne, 3 October 2014 – Ceva Santé Animale, the global veterinary health group, has invested €18 million in renovating and extending its sterile products plant in Libourne. The new industrial facility was inaugurated on 3 October and will increase injectable drug production capacity.
Ceva merges all R&D activity and nominates Dr. Steve Chu as member of the Executive Committee >
Libourne 4th September 2014 - Ceva Santé Animale announced the appointment of Dr.Chu to its executive committee with responsibility for all R&D activities. The move recognises the growing importance of biotechnology and the resulting convergence of pharmaceutical and biological research. Dr.Chu joined Ceva in 2011 and has an outstanding record throughout his 30 year career in veterinary research,...
Mérieux Développement becomes a shareholder of Ceva Santé Animale >
Ceva Santé Animale announces the arrival of a new shareholder, Mérieux Développement, the investment company of Institut Mérieux.
Mid-year results >
Ceva attracts strong investor support for 4th LMBO and returns to double-digit growth in first 6 months of 2014